The Immunoinhibitory Role of CD200-CD200R1 Signaling in Experimental Stroke

点击翻译按钮获取中文摘要

DESCRIPTION (provided by applicant): Emerging data suggests that stroke-induced inflammation significantly contributes to neuronal injury and clinical outcome. Local inflammatory responses following cerebral ischemia have highlighted a pivotal role for the innate immune system in the brain's response to injury, including the activation of microglia and macrophages. Cell-surface receptors (e.g., CD200R1) on microglia and other myeloid-derived cells directly interact with specific endogenous ligands (e.g ., CD200) expressed on neurons and act to suppress pro- inflammatory signaling by maintaining microglia in a "resting state". Normally these inhibitory mechanisms are required to keep the brain an immune-privileged site. When these interactions are broken, however, microglia can become disinhibited and enter a state of tonic activation, thereby exacerbating injury and worsening outcome. Thus, regulation of microglia after injury is crucial. Recent studies investigating the imbalance of CD200-CD200R1 signaling in models of neurodegenerative disease support the hypothesis that this interaction may also be disrupted following stroke. Preliminary data from our lab suggests that CD200 protein expression levels are decreased in the ischemic hemisphere early after experimental stroke, indicating that the inhibitory 'brake' on microglia is removed. Interestingly, we show a concurrent increase in CD200R1 protein levels after stroke, which coincided with an increased number of activated microglia and peripheral leukocyte recruitment. In this proposal we intend to elucidate the role of CD200-CD200R1 inhibitory signaling in stroke. In Aim 1 we will explore the functional consequences of these neuronal-glial interactions using conditional neuronal CD200 knockout and CD200R1 (global) knockout mice. Aim 2 will continue our mechanistic study of CD200R1- mediated inhibition by examining the local (microglia) and peripheral (leukocyte) contributions to stroke using CD200R1-/- bone marrow chimeras. Finally, Aim 3 will employ a small molecule CD200R1 agonist (CD200-Fc) for proof-of-principle of a therapeutic strategy to treat stroke. The overall goal of this proposal is to investigate the immunoregulatory mechanisms underlying microglia activation in brain injury and determine the efficacy of temporally suppressing microglia/myeloid activation to promote better outcomes and enhance recovery after stroke.